received funding from Paris Sciences et Lettres University/lUniversit Cte dAzur (PSL/OCAV)
and AstraZeneca: Speaking and Teaching, Tsunamasa Watanabe: Nothing to Disclose, Masaru Enomoto: Nothing to Disclose, Carmen Preda: Nothing to Disclose, Masanori Atsukawa: Nothing to Disclose, Sebastin Marciano: Nothing to Disclose, Son Do: Nothing to Disclose, Daniel Huang: Nothing to Disclose, Christopher Wong: Nothing to Disclose, Haruki Uojima: Nothing to Disclose, Hirokazu Takahashi: Nothing to Disclose, Htet Htet Toe Wai Khine: Nothing to Disclose, Takashi Honda: Nothing to Disclose, Norio Itokawa: Nothing to Disclose, Min Seok Go: Nothing to Disclose 403 FACTORS AND PREDICTION MODEL OF HBSAG RELAPSE AFTER ACHIEVING CLINICAL CURE IN CHB PATIENTS WITH PEG IFN-2B Jing Chen 1 fei yan 1 Jiayin Wang 2 Jing Liang 2 Jun Li 2 Fang Wang 2 Qing Ye 2 Yanying Gao 2 Weili Yin 2 Fei Tang 2 Huiling Xiang 2 , 1 The Third Central Clinical College of Tianjin Medical University, 2 Tianjin Third Central Hospital Background: Due to the existence of cccDNA in hepatocytes, there is still a portion of patients with HBsAg relapse after HBsAg seroclearance with interferon, and the predictive factors of whether HBsAg is recurrent are still in the exploratory stage
Immune layer: Thymosin alpha-1 for those with documented Th2-dominant immune profiles seeking to restore balance
and chow diet T.2918.4x5R sourced from Inotiv
